Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(2)
•••
Comment by ANALIAS00on May 17, 2019 12:30pm
91 Views
Post# 29755957

RE:RE:JPM Seller using CIBC?

RE:RE:JPM Seller using CIBC?They said they knew that Caisse de dpt sold some shares last year but they would know only next year if they sold more in 2019. They said they do not speak to them.
SPCEO1 wrote:

I believe the Caisse de depot was mentioned but that was when French was being spoken so one of the French speakers should confirm that.

I certainly cannot figure out why anyone would be anxious to sell. It seems like this is now one of Buffett's proverbial "fat pitches"

Wino115 wrote: It seems that way. For those of you who went to Annual Meeting, since they would have looked at the registry to see voting, was there at least any speculation on the part of the CFO or someone there as to who the consistent and urgent seller is? They clearly see shareholding changes via Compushare so must know who it is or at least have a very good idea by now.

What's the best guess?

 



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities